Grunenthal CEO Claims German Reimbursement Hurdle Is Fair, As Pain Drug Palexia Rolls Out Across Europe
German reimbursement authority’s strong emphasis on drugs’ added benefit is logical, opines Grunenthal CEO Harald Stock. And all health care systems will eventually move the same way.
You may also be interested in...
Stada spends $537 million on Grünenthal's branded product portfolio in Central and Eastern Europe and Spirig's generics business in Switzerland.
Accessing IMS Health’s European electronic health records and jointly building a customized data analysis platform will inform AstraZeneca’s R&D priorities and support outcomes claims of newly-launched drugs.
Based on a sales rep’s comments overheard at a pharmacist meeting, FDA warns Ortho-McNeil-Janssen about making unsubstantiated claims for pain killer Nucynta. The general pain relief claim granted the drug does not qualify it for use in the chronic pain condition discussed by the sales rep, FDA says.